VAP development according to the National Healthcare Safety Network criteria. The patients were categorized into four groups: EO if VAP occurred within 4 days of intubation and hospital admission; LO if VAP occurred after 4 days of admission; EL if VAP occurred within 4 days of intubation, but after the fourth hospitalization day; and LL if VAP occurred after the fourth day of intubation and hospitalization. Out of the 394 VAP episodes, 63 (16%) were EO episodes, 331 (84.0%) were LO episodes, 40 (10.1%) were EL episodes and 291 (73.1%) were LL episodes. The isolated microorganisms were comparable among the four groups, with a similar rate of potentially multidrug resistant organisms in the EO-VAP (31.7%), LO-VAP (40.8%), EL-VAP (37.5%) and LL-VAP (43.3%) samples. The hospital mortality was 24% for EO-VAP cases, 28% for LO-VAP cases, 40% for EL-VAP cases and 49% for LL-VAP cases. However, in the adjusted multivariate analysis, neither LO-VAP, EL-VAP nor LL-VAP was associated with an increased risk of hospital mortality compared with EO-VAP (OR, 0.86 95% CI, 0.34-2.19; 1.22; 95% CI, 0.41-3.68, and 0.95; 95% CI, 0.43-2.10, respectively). In this study, the occurrence of potential multidrug resistant pathogens and the mortality risk were similar regardless of VAP timing from hospital admission and intubation. The bacterial isolates obtained from the VAP cases did not follow an early vs. late-onset pattern, and thus, these terms may not be clinically helpful.
Introduction
Ventilator-associated pneumonia (VAP) is a common device-related healthcare-associated infection (HAI), with an incidence in critically ill patients ranging between 6 and 52% [1] [2] [3] . VAP remains a principal cause of morbidity, mortality and economic burden in intensive care units (ICUs) [4] . In a recent study, VAP was the third most common HAI infection, accounting for 31.7% of the annual cost of HAIs to the American health care system [5] . Additionally, it accounts for approximately half of all antibiotics prescribed to critically ill patients [6] .
The concept of early and late-onset VAP was introduced in 1986 by Mandelli and colleagues [7] . Traditionally, early onset VAP is caused by antibiotic-sensitive bacteria and has a better prognosis. In contrast, late-onset VAP is more likely to be caused by multi-drug resistant organisms (MDROs) and is associated with increased mortality and morbidity [8] . However, there is widespread variation among researchers in defining the exact time that differentiates early from late VAP, with the time for ''early'' ranging from 2 to 6 days in the published data [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Conflict also exists in selecting the inception point; is it the date of admission or the date of intubation/device? [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Uncertainty exists in the current literature as to whether the classification of early vs. late VAP is clinically important [11, [17] [18] [19] [20] . Furthermore, this labeling does not clearly account for ''early onset VAP'' in patients with prolonged hospital stays. Compared with patients who are recently admitted and develop ''early onset VAP,'' patients with extended hospitalization who subsequently develop ''early onset VAP'' may constitute a special population, with distinctive risk factors and microbial flora, thus requiring careful thought when selecting their empiric antibiotic regimen and prevention measures. Therefore, we performed this study to ascertain if in fact this categorization still bears any medical significance and also to assess the most prevalent microorganisms responsible for VAP in these groups.
Materials and methods

Patients and setting
This prospective observational cohort study was performed in a 21-bed closed medical-surgicaltrauma adult ICU at King Abdulaziz Medical City in Riyadh, Saudi Arabia, from August 1, 2003, to December 31, 2010. The ICU admitted approximately 900 patients annually and was covered by onsite board-certified intensivists 24 h per day, 7 days per week [21] with a nurse-to-patient ratio of approximately 1:1. The hospital was a 900-bed tertiary-care center, accredited by the Joint Commission International, and had an active Infection Prevention and Control Program that collaborated with the ICU medical and nursing staff to ensure the implementation and monitoring of infection control practices. In this study, all patients on mechanical ventilation (MV) for more than 48 h were prospectively followed during their ICU stay. We excluded patients who were transferred from other hospital as well as patients with burns, do-not-resuscitate orders and brain death. The Institutional Review Board and King Abdullah International Medical Research Center ethics committees of National Guard Health Affairs, Riyadh, approved this study and waived the requirement for informed consent because this was a prospective observational study using data commonly documented for all patients in our ICU department.
Diagnosis, definition and classification of ventilator associated pneumonia
One investigator made daily rounds in the ICU to identify patients with clinical signs of VAP. All patients with suspected VAP were prospectively and independently reviewed by another investigator, who confirmed the diagnosis. VAP was defined as pneumonia that developed more than 48 h after endotracheal intubation [8, 9, 22] . VAP was diagnosed clinically based on the Centers for Disease Control and Prevention criteria as two or more serial chest radiographs with at least 1 of the following: new, progressive, or persistent infiltrates; consolidation; or cavitation; with two of the following: core temperature ≥38.5 or ≤36 • C; leukocytosis (≥12,000 mm −3 ); leukopenia (white blood cell <1500 mm −3 ); or new onset purulent bronchial secretions, without other causes and a significant positive culture from blood, bronchoalveolar lavage or endotracheal aspirate, or a culture from another relevant site of infection [23] .
In this study, the patients were categorized into four groups depending on the timing of VAP onset from intubation and hospital admission: (1) the early onset (EO)-VAP group included patients who developed VAP within the first 4 days of invasive mechanical ventilation and of hospitalization; (2) the late-onset (LO)-VAP group included those who developed VAP after the fourth day of hospitalization; (3) the early late (EL)-VAP group included those who developed VAP within the first 4 days of intubation, but after the fourth day of hospitalization; and (4) the late-late (LL)-VAP group included those who developed VAP after the fourth day of intubation and hospitalization [8] [9] [10] 24] .
We defined Pseudomonas aeruginosa, Acinetobacter baumannii and Klebiella pneumoniae as potential multi-drug resistant organisms (MDROs) [25] . All patients were followed to hospital discharge, and only the first episode of VAP was included in this study.
Sampling
All patients with clinical criteria indicative of VAP underwent endotracheal aspiration sampling. Endotracheal aspiration was performed with a sterile technique using a 50-cm, 10-12 F suction catheter (Tyco; Tyco Healthcare Ireland Limited, Ireland) with a mucus collection tube (Mucus Trap; Amsino International Inc.; Pomona, California). The catheter was introduced through the endotracheal tube for at least 30 cm. Gentle suctioning was performed, and the aspirate (volume ≥1 mL) was collected for evaluation [26] .
Microbiology
Endotracheal aspirate cultures were collected in a sterile sputum trap and then sent to the microbiology laboratory. The specimens were then plated on sheep blood agar, chocolate, and MacConkey agar. All plates were incubated for at least 48 h in a 5% carbon dioxide incubator at 37 • C. The isolates were characterized by colony morphology and Gram staining. The microbiological growth of the endotracheal aspirate was classified as rare, light, moderate, or heavy based on the number of colonies on the plate. The identification of the organism was performed using a Vitek ® II system (North Carolina, USA) and API 20E ® test kits (bioMerieux, Inc., Missouri, USA). The susceptibility of the clinical isolates to antibiotics was determined by the Vitek ® II system (North Carolina, USA), while the E-test was used for confirmation when necessary.
If multiple organisms were isolated from a single sample, all of their data were entered in the statistical analysis (Table 2 ).
Additional collected data
The same investigator recorded other relevant data by reviewing the patients' medical records. The following clinical information were captured: the demographic data, admission category (medical, surgical or trauma), primary admission diagnosis depending on the system involved, source of admission, patient's cute physiology and chronic health evaluation (APACHE) II score [27] , injury severity score (ISS) for trauma patients [28] , presence of chronic illnesses (diabetes mellitus, hypertension, chronic obstructive pulmonary disease or an immunocompromised state), admission Glasgow Coma Scale score (GCS) with coma defined as GCS <9, presence of shock on admission defined as requiring vasopressors or inotropes, except for dopamine of <5 g/kg/min, ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO 2 /FiO 2 ) and diagnosis of acute respiratory distress syndrome [29] on ICU admission. Data obtained from the VAP database included the location where the intubation was performed, type of intubation (elective vs. emergent), presence of pre-determined VAP risk factors (the use of nasogastric vs. orogastric tubes, witnessed aspiration, use of H 2 blockers, neuromuscular blockers and prior antibiotic therapy for >7 days, traumatic intubation, unplanned extubation, and failed extubation) and respiratory culture results. Pseudomonas aeruginosa, Acinetobacter baumannii and Klebiella pneumoniae were considered to be potential MDROs. We also recorded the following outcomes from the ICU database: ICU and hospital mortality, tracheostomy requirements, duration of MV and length of stay in the ICU and hospital.
Statistical analysis
The patient demographics, clinical characteristics, and risk factors were described as the means with standard deviations for continuous data or frequencies with percentages for categorical data. Chi-square, Fisher's exact or Student t tests, as appropriate, were used to evaluate differences among the study groups. To study the impact of VAP onset timing on patient outcomes, we ran multivariate logistic regression analyses. The independent variables entered in the models were clinically relevant factors and the baseline characteristics that were significantly different among the groups of patients. These variables included: age, gender, APACHE II score, body mass index, GCS, creatinine, INR, bilirubin, admission diagnosis, admission category, chronic co-morbidities (respiratory, cardiovascular, renal, neurological), diabetes, hypertension, vasopressor use, location before referral to the ICU, acute respiratory distress syndrome, failed extubation, accidental extubation, orogastric vs. nasogastric tube and prolonged use of antibiotics. The results for dichotomous outcomes (ICU and hospitality and tracheostomy) are presented as odds ratios (ORs) with 95% confidence intervals (CIs). The results of continuous outcomes (ICU and hospital length of stay) were presented as beta coefficients with 95% CIs. If the regression beta coefficient is positive, the interpretation is that for every 1-unit increase in the predictor variable, the dependent variable will increase by the unstandardized beta coefficient value. All statistical analyses were conducted using the Statistical Analysis System (SAS, version 9.0; SAS Institute, Cary, NC).
Results
Patient characteristics
There were 394 episodes of VAP during the study period. Of these, 63 (16%) were EO-VAP, 331 (84%) were LO-VAP, 40 (10.1%) were EL-VAP and 291 (73.1%) were LL-VAP. Table 1 describes the characteristics of the four groups. Patients in the EO-VAP group were younger (35.2 ± 17.8 years); had lower body mass indices (25.6 ± 6.0 kg/m 2 ), APACHE II scores (19.6 ± 5.1), and higher PaO 2 /FiO 2 ratios (270 ± 99); and were more likely to be intubated in (83.9%) and admitted from (69.8%) the emergency department compared with those with LO-VAP. Individuals in the EL-VAP group had a similar age, body mass index, PaO 2 /FiO 2 ratio, platelet counts, source of referral and location of intubation, but a lower APACHE II score (21.8 ± 7.2 vs. 25.6 ± 9.2, P = 0.01), compared to those in the LL-VAP group.
Microbiological patterns
The VAP microbiology is described in Table 2 . A total of 293 VAP-related organisms were isolated during the study period from August 1, 2003 Gram-negative bacilli were the most frequently isolated agents in the four groups. The three most frequent microorganisms isolated in the EO-VAP group were Hemophilus influenzae (25.4%), Acinetobacter baumannii (12.7%), and methicillinsensitive Staphylococcus aureus (MSSA) (11.1%). In the EL-VAP group, the most common microorganisms were MSSA (20%), A. baumannii (15%) and Pseudomonas aeruginosa (15%). In the LL-VAP group, the most common microorganisms were A. baumannii (18.6%), P. aeruginosa (16.2%), Enterobacter species (5.5%) and MSSA (5.5%). 16 .0%, p = 0.02). The isolated pathogens in the EO-VAP group were similar to those in the EL-VAP group, except for H. influenza (2.5% vs. 25.4%, p = 0.002). Additionally, the organisms responsible for EO-VAP were comparable to those responsible for LL-VAP, except for H. influenza (25.4% vs. 2.1%, p = 0.0001) and S. pneumonia (7.9 vs. 2.4, p = 0.04), which were more common in EO-VAP cases. The isolated pathogens for EL-VAP were comparable to those isolate from LL-VAP, except for MSSA (20% vs. 5.5%, p = 0.003).
Methicillin-resistant Staphylococcus aureus (MRSA) and the potential MDROs (P. aeruginosa, A. baumannii and K. pneumonia) were commonly isolated in the four groups (EO-VAP: 31.7%, LO-VAP: 40.8%, EL-VAP: 37.5% and LL-VAP: 43.3%). While P. aeruginosa was significantly more common in LO-VAP and LL-VAP cases compared with EO-VAP cases (16.2% vs. 4.8%, p = 0.02), the rates of A. baumannii, K. pneumonia and MRSA were similar in these groups. Table 3 shows the outcomes of the four groups of patients in this study. The ICU mortality (p = 0.01), hospital mortality (p = 0.002) and tracheostomy (p = 0.03) rates in the EO-VAP group were significantly lower than those in the LO-VAP group, but were similar to those of the EL-VAP group (12.7% vs. 25.0%, p = 0.11; 28.3% vs. 40.0%, p = 0.08; and 44.4% vs. 50.0%, p = 0.58, respectively). Likewise, there were insignificant differences in the outcomes of patients in the EL-VAP and LL-VAP groups.
Patient outcomes
Outcome predictors
In the adjusted multivariate logistic regression analysis, LO-VAP was not associated with increased hospital (OR, 0.87 95% CI, 0.35-2.19, p = 0.77) or ICU (OR, 0.98; 95% CI, 0.45-2.15, p = 0.97) mortality compared with EO-VAP, but LO-VAP was associated with an increased risk for tracheostomy (OR, 2.26; 95% CI, 1.27-4.04, p = 0.006). Further, neither EL-VAP nor LL-VAP was associated with increased ICU (OR, 0.95; 95% CI, 0.27-3.30, and OR, 0.86; 95%CI, 0.34-2.19, p = 0.76, respectively) or hospital mortality (OR, 1.22; 95% CI, 0.41-3.68, and OR, 0.95; 95% CI, 0.43-2.10, respectively) compared with EO-VAP (Table 4 ). However, LL-VAP was associated with an increased risk of tracheostomy (OR, 2.49; 95% CI, 1.36-4.53, p = 0.003) compared with EO-VAP. The predictors of ICU mortality included age (OR, 1.02; 95% CI 1.0-1.03, p = 0.04), chronic liver disease (OR, 5.63; 95% CI 2.49-12.78, p < 0.0001), and chronic immunosuppression (OR, 2.80; 95% CI, 1.22-6.42, p = 0.02). The predictors of hospital mortality were age (OR, 1.03; 95% CI 1.02-1.05, p < 0.001), APACHE II score (OR, 1.08; 95% CI, 1.04-1.12, p < 0.001) and chronic immunosuppression (OR, 2.96; 95% CI, 0.98-8.93, p = 0.05).
Discussion
Our study found that the microorganisms responsible for VAP were generally comparable regardless of the length of hospitalization or the duration of mechanical ventilator use before VAP onset. However, Hemophilus influenza was significantly more common and P. aeruginosa was less frequent in the EO-VAP group compared with the LO-VAP group. Additionally, there was no significant difference in the presence of MRSA and potential MDROs (A. baumannii, K. pneumoniae) between the groups. Further, although mortality was highest in the LL-VAP group, the time of VAP onset was not independently associated with mortality. Prior studies have shown a higher involvement of MDROs in LO-VAP compared with EO-VAP [30] [31] [32] [33] . However, globally, recent data from several studies have revealed that the causative pathogens in EO-VAP were mostly Gram-negative organisms, with a high prevalence of MDROs [11, 17, 18, 20, 25, 34] . In 2000, Ibrahim et al. reported that except for P. aeruginosa, both EO-and LO-VAP were caused by similar organisms [18] . In a recent prospective multicenter study conducted in 27 ICUs from nine European countries, Martin-Loeches and associates illustrated that 50.7% of EO-VAP episodes were associated with potentially MDROs [25] . An analysis of 496 patients with VAP from multiple centers in North America, South America, Europe and Australia demonstrated that 43.3% of the organisms isolated from EO-VAP were MDROs [17] . Additionally, a prospective surveillance study conducted in 73 hospitals in 10 Asian countries on 997 patients with VAP found that Acinetobacter species, P. aeruginosa, S. aureus, and K. pneumonia were the most common causes of both EO-and LO-VAP [35] . Similarly, our data indicate that Gram-negative microorganisms are the main isolates found in VAP cases, regardless of the diagnosis timing from hospital admission and invasive mechanical ventilation. , diabetes, hypertension, vasopressor use, location before referral to the ICU, acute respiratory distress syndrome, failed extubation, accidental extubation, orogastric vs. nasogastric tube and prolonged antibiotics. § Beta coefficient: if the regression beta coefficient is positive, the interpretation is that for every 1-unit increase in the predictor variable, the dependent variable will increase by the unstandardized beta coefficient value. For example, the presence of late onset VAP in our model increased ICU length of stay by 6.12 days compared with early onset VAP. This suggests that the bacteriology of VAP may not follow an ''early versus late'' pattern and that there may be a microbiological shift in the pathogens responsible for ''early onset'' VAP favoring MDROs.
Our findings are of paramount importance as the current practice guidelines suggest that patients with EO-VAP and no risk factors for MDROs should be treated with narrow spectrum antibiotics [8] . However, inadequate antimicrobial therapy, whether with inappropriate coverage or delayed initiation, has been associated with higher hospital mortality in patients with hospital-acquired pneumonia or VAP [36] [37] [38] . Kollef and colleagues demonstrated that the inappropriate initial antibiotic therapy of VAP cases attributed to potentially antibioticresistant Gram-negative bacteria was associated with a greater 30-day mortality [39] . Heyland et al., in a multicenter, randomized trial of 740 critically ill patients with VAP from 28 ICUs in Canada and the United States showed that in patients who had an infection due to Pseudomonas species, Acinetobacter species, and MDR Gram-negative bacilli, the adequacy of initial antibiotics (84.2% vs. 18.8%, p < 0.001) and microbiological eradication of infecting organisms (64.1% vs. 29.4%, p < 0.05) was higher in the combination group compared with the monotherapy group [40] . Thus, it may be reasonable to use broad spectrum combination antibiotics as an empirical therapy for all VAP cases followed by a prompt de-escalation plan, especially in institutions with a high prevalence of MDROs.
Our study demonstrated that the time of VAP onset was not an independent predictor of either ICU or hospital mortality. Other investigators have had similar observations. Mosconi et al. compared patients with early and late-onset pneumonia and discovered a similar rate of mortality in the two groups [41] . This was also observed by Heyland et al. [42] and by Ibrahim et al. [18] . Giantsou et al. investigated this question, focusing on diagnosing pneumonia by bronchoalveolar lavage, and came to the same conclusion [11] . Hedrick et al. were unable to detect any significant differences in mortality between EO-and LO-pneumonia [43] . In the current study, multivariate analysis showed that higher APACHE II scores and the presence of chronic liver disease were associated with shorter ICU and hospital lengths of stay. This could be explained by the fact that patients with these conditions died earlier and thus had a shorter length of stay.
The strengths of this study include the large sample size and prospective data collection. Our study has several limitations. First, this was a single center study, so our patient population may not be similar to those at other institutions and our results may not be applicable to other ICUs. Second, we used the CDC criteria [23] for diagnosing healthcare-associated pneumonia, which may overestimate VAP incidence [18] . Third, the bacterial isolates from the VAP cases may not reflect the true etiologic pathogens because more stringent diagnostic procedures, such as bronchoalveolar lavage, were not performed in most cases. However, the optimal diagnostic approach for VAP has not been well established [44] .
Conclusions
This study demonstrated that in most VAP cases, the isolated microorganisms were potential MDROs, regardless of the duration of hospitalization or mechanical ventilation use before VAP onset. Further, in our opinion, the old concept of differentiating pathogens based on EO-and LO-VAP may no longer be helpful in choosing the correct empirical antibiotic therapy. Our findings also emphasize the need for ICU-specific information on VAP-causative organisms to facilitate appropriate empiric antimicrobial therapy. Finally, out data support what seems to be a global shift in the pathogens causing ''early VAP''.
Key message
-The microorganisms responsible for VAP were generally similar regardless of the preceding length of hospitalization or time on mechanical ventilator. -There were no significant differences in the presence of potentially multidrug resistant organisms, mainly A. baumannii, K. pneumonia and MRSA, between early and late-onset VAP cases. -The time of onset of VAP was not independently associated with increased mortality. -There appears to be a shift in the pathogens causing ''early onset VAP''. manuscript. HB: study design and critical review of the manuscript. YA: study design, data interpretation and critical review of the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of this work.
